Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions.
CD30 has emerged as a critical marker of diagnosis, prognosis, and therapeutic strategies of lymphomas. The introduction of brentuximab vedotin (BV) (Adcetris), an antibody-drug conjugate targeting CD30, has significantly advanced the treatment landscape for multiple lymphoma types, demonstrating enhanced efficacy and manageable safety profiles in CD30+ lymphomas patients. However, drug resistance is observed in few patients. Concurrently, innovative therapeutic strategies targeting CD30, such as chimeric antigen receptor T-cells therapies and bispecific antibodies, are in development. This underscores a strong and ongoing research effort aimed at improving the management of patients with CD30+ lymphomas.